Cyxone presents T20K program at the ECTRIMS conference
Cyxone presents the latest results on the T20K project at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam.Cyxone is together with its research collaboration partners at the Medical University of Vienna (MUV) investigating T20K for multiple sclerosis in preclinical research models. Recent discoveries have unveiled that T20K acts as a novel modulator of the k-opioid receptor (KOR). New data from therapeutic preclinical models demonstrated that a combination of T20K and a KOR drug show encouraging positive results: disease